Overview of pharmacologic therapy for the treatment of dyslipidemia.
Although the National Cholesterol Education Program Adult Treatment Panel III (ATP III) guidelines stress the importance of nonpharmacologic lipid modification interventions such as diet and exercise, the guidelines also recognize that many patients will require drug therapy to achieve low-density lipoprotein cholesterol (LDL-C) target goals. Currently available lipid-modifying drugs include bile acid sequestrants (or resins), fibrates, nicotinic acid, and statins, with each class exerting different effects on the lipid profile. In addition, nonprescription agents such as plant stanols and sterols have been shown to be effective in modifying plasma lipids. Of these agents, the statins are the most effective, most widely prescribed, and best-tolerated form of lipid-lowering drug therapy. New formulations of other drugs, such as niacin and bile acid sequestrants, can also improve treatment regimes and reduce side effects, thereby improving patient compliance with these therapies. In patients who have high levels of LDL-C and triglycerides together with low concentrations of high-density lipoprotein cholesterol (HDL-C), combination therapy may be required. Ezetimibe, a selective cholesterol absorption inhibitor, is the first of a new class of lipid-lowering agents and provides a new agent for the management of patients with dyslipidemia. Data from the ezetimibe clinical development program suggests that this agent can be used alone or in combination with statins to reduce LDL-C, improve compliance, and bring more patients to ATP III target goal.
Lipsy
Robert J
RJ
Health Net of Arizona, 930 North Finance Center Dr., Tucson, Arizona 85710, USA. Robert.J.Lipsy@az.health.net
D000499:Allylamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000191:economics / Q000627:therapeutic use*; D001647:Bile Acids and Salts / Q000037:antagonists & inhibitors; D008078:Cholesterol, LDL / Q000037:antagonists & inhibitors / Q000097:blood; D000069472:Colesevelam Hydrochloride; D015248:Gemfibrozil / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000188:drug therapy*; D008082:Lipotropic Agents / Q000627:therapeutic use; D009539:Nicotinic Acids / Q000627:therapeutic use; D010840:Phytosterols / Q000627:therapeutic use; D008517:Phytotherapy; D017410:Practice Guidelines as Topic
D000924:Anticholesteremic Agents; D001647:Bile Acids and Salts; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008082:Lipotropic Agents; D009539:Nicotinic Acids; D010840:Phytosterols; D000499:Allylamine; D000069472:Colesevelam Hydrochloride; D015248:Gemfibrozil